학술논문

Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease
Review
Document Type
Report
Source
Cardiology and Therapy. December 2021, Vol. 10 Issue 2, p325, 24 p.
Subject
United States
Language
English
ISSN
2193-8261
Abstract
Author(s): Eman Abdelghani [sup.1] [sup.3] , Clifford L. Cua [sup.2] [sup.3] , Jean Giver [sup.1] [sup.3] , Vilmarie Rodriguez [sup.1] [sup.3] Author Affiliations: (1) grid.240344.5, 0000 0004 0392 3476, Division [...]
Thrombosis is one of the most frequent complications affecting children with congenital heart disease (CHD). Palliative and reparative cardiac surgeries are some of the main players contributing to the thrombosis risk in this patient population. Additional risk factors related to the CHD itself (e.g., cardiac dysfunction, arrhythmias, and polycythemia in cyanotic cardiac disorders) can contribute to thrombogenicity alone or combined with other factors. Thrombotic complications have been recognized as a significant cause of morbidity and mortality in this patient population. Here, we provide an overview of the pathophysiology and risk factors for thrombosis as well as the indications for and use of different anticoagulation, antiplatelet, and thrombolytic agents. In addition, we describe some of most common thrombotic complications and their management in the pediatric CHD population.